Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As a young physiology student Tipu Aziz was inspired by watching grainy videos from the 1970s showing patients undergoing ...